The impact of Recombinant Human Brain Natriuretic Peptide Therapy following Percutaneous Coronary Intervention (PCI) on AMI patients is a topic of significant interest and debate. While some studies suggest potential benefits, others report neutral findings, highlighting the need for further investigation. This article explores the clinical value of rhBNP as an adjuvant therapy after PCI in AMI patients, focusing on its effects on cardiac function, myocardial injury, and inflammatory responses. The study retrospectively analyzed data from 104 AMI patients who underwent PCI, comparing a control group (admitted from September 2021 to December 2022) with an observation group (admitted from January 2023 to December 2024) that received adjunctive rhBNP therapy. The results showed that the observation group had significantly better overall efficacy, with more pronounced improvements in cardiac function, reduced myocardial injury markers, and lower inflammatory stress levels. Moreover, the incidence of major adverse cardiovascular events (MACE) was significantly lower in the observation group, reinforcing the potential of rhBNP to confer lasting cardiovascular benefits. However, the study's limitations, including its single-center design and relatively small sample size, should be acknowledged. Further large-scale, multi-center, prospective randomized controlled trials are needed to robustly establish the efficacy, safety, and optimal role of rhBNP within standardized AMI treatment pathways.
